Regeneron (REGN +1.7%) gets a lift today as Goldman reiterates its Buy recommendation and raises...

|About: Regeneron Pharmaceuticals, ... (REGN)|By:, SA News Editor

Regeneron (REGN +1.7%) gets a lift today as Goldman reiterates its Buy recommendation and raises its price target on the shares to $215 from $196 citing relative YTD underperformance versus the Nasdaq Biotech index and a strong Eylea launch.